Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    Cancer screening in 2026: who should be screened, for what, and when

    Cancer screening looks for cancer or pre-cancer in people who have no symptoms.[1] In the US, the USPSTF recommends screening for breast, cervical, colorectal and lung cancer in defined age and risk groups, and leaves PSA prostate screening at 55 to 69 to individual choice.[2][3][4][5][6] The NHS in England runs its own programmes with different ages and intervals.[7]

    Editor reviewedStrict sourcingUpdated ExplainerHealth and medicine, Life sciences

    Cancer screening means testing people who feel well, to find cancer or pre-cancer before symptoms appear.[1] It is different from checking out a symptom. If you have a symptom, see cancer warning signs and talk to a doctor rather than waiting for a screening invitation. As of October 2026, the main US guidelines date from 2018 to 2024, and 2026 brought changes to cervical and UK prostate screening.[8][9]

    This page is general information, not medical advice. Guidelines describe people at average risk. Talk to a clinician about what fits your age, history and family risk.

    How screening works

    A screening test sorts people into “probably fine” and “needs more tests”. It is not a diagnosis. In the NHS’s words, screening tests are not perfect and can lead to difficult decisions about further tests or treatment. Having one is a personal choice.[10]

    In the US, the main guideline body is the US Preventive Services Task Force. It grades each recommendation A to D, or I where the evidence is insufficient, and does not consider cost.[11] Its advice covers only people without symptoms.[12] In the UK, an independent committee, the UK NSC, advises all four NHS systems on which programmes to offer.[13]

    USPSTF grades rest on the certainty of net benefit, so the same test can earn an A in one age band and a C or I in another.[11][4] The harms are counted too. For mammography the USPSTF lists false positives with extra testing, overdiagnosis and overtreatment, and radiation exposure.[14] For PSA testing it calls the benefit small and the harms common, including biopsies after false positives and overtreatment.[15] UK policy is stricter about outcomes. Its position is that finding more early cancers does not prove fewer deaths, so falls in late-stage disease cannot yet replace cancer mortality as the measure of benefit.[16]

    What the guidelines recommend

    The table attributes each age and interval to the body that sets it. Figures apply to people at average risk without symptoms.

    CancerUSPSTF (US)NHS England
    BreastMammogram every 2 years, ages 40–74 (B, 2024)[2]Ages 50–70; self-referral over 70[7]
    CervicalPap test every 3 years at 21–29; at 30–65, Pap every 3 years, HPV test every 5 years or co-test every 5 years (2018; update in progress)[3]Every 5 years, ages 25–64[7]
    ColorectalAges 45–75 (A at 50–75, B at 45–49); selective at 76–85 (C) (2021)[4]Home FIT kit every 2 years, ages 50–74[7]
    LungYearly low-dose CT, ages 50–80, 20 pack-years, smoking now or quit within 15 years (B, 2021)[5]Ages 55–74 who have ever smoked, in parts of England[17]
    ProstateIndividual decision at 55–69 (C); not at 70+ (D) (2018; update in progress)[6]UK NSC (May 2026): PSA every 2 years only for men 45–61 with a BRCA2 variant and family history[9]

    For colorectal screening, the USPSTF lists several acceptable tests: FIT or a high-sensitivity stool blood test every year, stool DNA-FIT every 1 to 3 years, CT colonography or flexible sigmoidoscopy every 5 years, or colonoscopy every 10 years.[18] Any abnormal stool test needs a follow-up colonoscopy.[19] Our buyer’s guide to at-home tests compares the stool and blood options.

    Gaps in the evidence

    The USPSTF found the evidence insufficient to judge mammography from age 75, and extra ultrasound or MRI for women with dense breasts.[20] Its 2021 colorectal recommendation does not include blood tests, which it said had limited evidence at the time.[21] Many deadly cancers, such as pancreatic and ovarian cancer, have no recommended screening option.[22] That gap is why multi-cancer blood tests such as Galleri attract attention. Their evidence is debated, as our analysis of multi-cancer early detection sets out.[22][23]

    What changed in 2026

    • Cervical self-sampling. In January 2026 the American Cancer Society accepted self-collected vaginal HPV samples for people aged 25 to 65, with a repeat test after 3 years if negative. A clinician-collected sample is still preferred.[8] The ACS also now asks for negative HPV tests at 60 and 65 before stopping.[24] In April 2026 ACOG endorsed HRSA guidelines that add self-collection every 3 years at ages 30 to 65.[25]
    • Targeted prostate screening in the UK. The UK NSC recommended against population PSA screening and for screening only a small high-risk BRCA2 group.[9]
    • New blood tests. The FDA approved a second colorectal screening blood test in July 2026. An advisory panel backed the first multi-cancer test in September, though the FDA had not decided by 11 October.[26][27][28]
    • An inactive USPSTF. The task force had not met for more than a year by September 2026. Its cervical and prostate recommendations are still marked “update in progress”.[29][3][6]

    Dated developments are logged in the cancer screening tracker. For prevention, see cancer prevention explained. For treatment, including immunotherapy, see the site’s cancer immunotherapy crash course.

    Next in the crash course

    More in Health & medicine

    Developing in Health

    Questions readers ask

    At what age should women start mammograms?

    The USPSTF's April 2024 recommendation is a screening mammogram every two years for women aged 40 to 74. The NHS in England offers breast screening to women aged 50 to 70.[2][7]

    When should colorectal cancer screening start?

    The USPSTF recommends colorectal screening from age 45 to 75 for adults at average risk. The NHS sends a home FIT kit every two years to people aged 50 to 74.[4][7]

    Who should get lung cancer screening?

    The USPSTF recommends a yearly low-dose CT scan for adults aged 50 to 80 with a 20 pack-year smoking history who still smoke or quit within the past 15 years.[5]

    Is PSA screening for prostate cancer recommended?

    The USPSTF says it should be an individual decision for men aged 55 to 69 and recommends against it from age 70. In May 2026 the UK NSC recommended screening only men aged 45 to 61 with a harmful BRCA2 variant and a relevant family history.[6][9]

    Can I do my own cervical screening test?

    In 2026 the American Cancer Society and the HRSA guidelines endorsed by ACOG added self-collected HPV samples as an option. The ACS says a negative self-collected test should be repeated in three years.[8][25]

    Does screening have downsides?

    Yes. The USPSTF lists false positives, overdiagnosis, overtreatment and, for mammography, radiation exposure among the potential harms.[14][15]

    Sources

    · 29 claims from 17 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      WHO distinguishes early diagnosis of symptomatic cancer from screening, which aims to find cancer or pre-cancer in people before symptoms develop. confirmedas of 2026-10-11

    2. [2]

      The USPSTF (April 2024) recommends biennial screening mammography for women aged 40 to 74 (grade B). confirmedas of 2026-10-11

    3. [3]

      The USPSTF's current cervical recommendation (August 2018) is cytology every 3 years at ages 21 to 29, and at 30 to 65 cytology every 3 years, high-risk HPV testing alone every 5 years or co-testing every 5 years; an update is in progress. confirmedas of 2026-10-11

    4. [4]

      The USPSTF (May 2021) recommends colorectal cancer screening for all adults aged 50 to 75 (grade A) and adults aged 45 to 49 (grade B), and selective screening at 76 to 85 (grade C). confirmedas of 2026-10-11

    5. [5]

      The USPSTF (March 2021) recommends annual low-dose CT lung screening for adults aged 50 to 80 with a 20 pack-year smoking history who smoke now or quit within the past 15 years (grade B). confirmedas of 2026-10-11

    6. [6]

      The USPSTF (May 2018) says PSA screening for men aged 55 to 69 should be an individual decision (grade C) and recommends against it at 70 and older (grade D); an update is in progress. confirmedas of 2026-10-11

    7. [7]

      In England the NHS offers cervical screening every 5 years at ages 25 to 64, breast screening at 50 to 70 (self-referral over 70), and a home bowel test kit every 2 years at 50 to 74. confirmedas of 2026-10-11

      • NHS screening · NHS · Cervical screening (retrieved 2026-10-11)
      • NHS screening · NHS · Breast screening (retrieved 2026-10-11)
      • NHS screening · NHS · Bowel cancer screening (retrieved 2026-10-11)
    8. [8]

      The American Cancer Society's January 2026 cervical guideline update accepts self-collected vaginal HPV samples for average-risk people aged 25 to 65 (clinician collection preferred), with repeat testing 3 years after a negative self-collected test. confirmedas of 2026-10-11

    9. [9]

      In May 2026 the UK NSC recommended targeted prostate screening, with a PSA test every 2 years, for men aged 45 to 61 who carry a harmful BRCA2 variant and have a family history of breast, ovarian, pancreatic or prostate cancer, and recommended against population screening. confirmedas of 2026-05-28

    10. [10]

      The NHS says screening tests are not perfect, can lead to difficult decisions about further tests or treatment, and are a personal choice. confirmedas of 2026-10-11

      • NHS screening · NHS · What your screening results mean (retrieved 2026-10-11)
      • NHS screening · NHS · Making an informed choice (retrieved 2026-10-11)
    11. [11]

      The USPSTF gives each recommendation a letter grade (A, B, C, D or an I statement) based on the strength of evidence and the balance of benefits and harms, and does not consider cost. confirmedas of 2026-10-11

      • About the USPSTF · US Preventive Services Task Force · What We Do (retrieved 2026-10-11)
      • About the USPSTF · US Preventive Services Task Force · What We Do (retrieved 2026-10-11)
    12. [12]

      USPSTF recommendations apply only to people without signs or symptoms of the condition. confirmedas of 2026-10-11

      • About the USPSTF · US Preventive Services Task Force · What We Do (retrieved 2026-10-11)
    13. [13]

      The independent UK National Screening Committee advises the NHS in all four UK nations on which screening programmes to offer. confirmedas of 2026-10-11

      • NHS screening · NHS · What types of screening are offered (retrieved 2026-10-11)
    14. [14]

      The USPSTF lists the potential harms of screening mammography as false positives leading to extra tests and procedures, overdiagnosis and overtreatment, and radiation exposure. confirmedas of 2026-10-11

    15. [15]

      The USPSTF says PSA screening offers a small potential benefit for some men, while many experience harms such as false positives, biopsies, overdiagnosis and overtreatment. confirmedas of 2026-10-11

    16. [16]

      The UK NSC's position (October 2026) is that surrogate outcomes such as fewer late-stage cancers cannot yet replace cancer-specific deaths as the main measure of screening benefit, because finding more early cancers does not necessarily mean fewer deaths. confirmedas of 2026-10-01

    17. [17]

      In parts of England, people aged 55 to 74 who have ever smoked may be invited to NHS lung cancer screening. confirmedas of 2026-10-11

      • NHS screening · NHS · Lung cancer screening (retrieved 2026-10-11)
    18. [18]

      The USPSTF's recommended colorectal screening strategies include FIT or high-sensitivity guaiac stool testing every year, stool DNA-FIT every 1 to 3 years, CT colonography or flexible sigmoidoscopy every 5 years, and colonoscopy every 10 years. confirmedas of 2026-10-11

    19. [19]

      Under the USPSTF recommendation, an abnormal stool-based test result needs follow-up colonoscopy. confirmedas of 2026-10-11

    20. [20]

      The USPSTF found the evidence insufficient (I statement) to assess screening mammography in women 75 or older, and supplemental ultrasound or MRI for women with dense breasts after a negative mammogram. confirmedas of 2026-10-11

    21. [21]

      The 2021 USPSTF colorectal recommendation does not include blood (serum) tests, urine tests or capsule endoscopy because of limited evidence. confirmedas of 2026-10-11

    22. [22]

      Galleri is a prescription blood test that looks for cancer-specific DNA methylation patterns in cell-free DNA, screens for more than 50 cancer types, and predicts where in the body a cancer signal originated. confirmedas of 2026-10-11

    23. [23]

      NHS-Galleri missed its primary endpoint; the rate of stage III or IV cancer across 12 prespecified cancer types did not differ significantly between groups after three rounds (incidence rate ratio 1.03, 95% CI 0.92 to 1.14). confirmedas of 2026-10-11

    24. [24]

      The ACS update recommends negative HPV tests at ages 60 and 65 before stopping cervical screening, citing high cervical cancer rates in people over 65. confirmedas of 2026-10-11

    25. [25]

      On 23 April 2026 ACOG endorsed updated HRSA Women's Preventive Services guidelines that add patient-collected HPV testing every 3 years as an option at ages 30 to 65, with clinician primary HPV testing every 5 years preferred. confirmedas of 2026-04-23

    26. [26]

      On 27 July 2026 the FDA approved Freenome's SimpleScreen CRC blood test for average-risk adults 45 and older; in the PREEMPT CRC study it detected 81.1% of colorectal cancers and 13.7% of advanced precancerous lesions, with 90.4% specificity, and Abbott will sell it in the US. A study investigator quoted by Freenome said a blood test offers another way to reach unscreened patients. confirmedas of 2026-07-27

    27. [27]

      On 23 September 2026 an FDA advisory panel voted 7-2 with one abstention that Galleri's benefits outweigh its risks, unanimously on safety, and 6-4 on effectiveness, for screening adults aged 50 and older; the FDA is not bound by the vote. confirmedas of 2026-09-23

    28. [28]

      As of 11 October 2026 Galleri's own site stated that the test has not been cleared or approved by the FDA; it is sold as a laboratory-developed test under CLIA and requires a prescription. confirmedas of 2026-10-11

    29. [29]

      As of September 2026 the USPSTF had not met for more than a year after its meetings were cancelled by HHS Secretary Robert F. Kennedy Jr. confirmedas of 2026-09-17

    Revision history (1)
    1. Page created.

    Created Oct 11, 2026. Last reviewed by an editor on Oct 11, 2026. Next scheduled review: Jan 11, 2027.

    Cite this page

    "Cancer screening in 2026: who should be screened, for what, and when." ContentLora, updated Oct 11, 2026. https://contentlora.com/explain/cancer-screening-explained

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    ☰ Contents